Related Experiment Video
Updated: Nov 3, 2025

Ultrasonic Assessment of Myocardial Microstructure
Published on: January 14, 2014
H2 FPEF score predicts atherosclerosis presence in patients with systemic connective tissue disease
Vladimir Vasilev1, Dejana Popovic2,3, Gorica G Ristic4
1School of Medicine, University of Belgrade, Belgrade, Serbia.
Insights
The H2FPEF score and TAPSE/PASP ratio can help diagnose atherosclerosis in systemic connective tissue disease patients. These tools offer clinical value beyond traditional risk factors for cardiovascular disease.
Area of Science:
- Cardiology
- Rheumatology
- Vascular Medicine
Background:
- Cardiovascular diseases are a leading cause of death in systemic connective tissue diseases (SCTD).
- Accelerated atherosclerosis in SCTD is not fully explained by traditional risk factors.
- Novel markers are needed to assess cardiovascular risk in SCTD patients.
Purpose of the Study:
- To investigate the predictive value of the H2FPEF score for heart failure with preserved ejection fraction.
- To evaluate the utility of the tricuspid annular plane systolic excursion (TAPSE)/pulmonary artery systolic pressure (PASP) ratio.
- To determine if these measures predict atherosclerosis in SCTD patients.
Main Methods:
- 203 SCTD patients underwent echocardiography, carotid ultrasound, and CT coronary angiography.
- Measurements included TAPSE/PASP, E/e', and calculation of the H2FPEF score.
- Atherosclerosis was defined by intima-media thickness or coronary artery calcium scoring.
Main Results:
- Atherosclerosis was present in 150/203 patients.
- The H2FPEF score significantly predicted atherosclerosis presence (HR 2.6, p < 0.001).
- Resting TAPSE/PASP predicted ischemia on stress echocardiography (HR 0.01, p = 0.004).
Conclusions:
- The H2FPEF score shows clinical value in diagnosing atherosclerosis in SCTD.
- Resting TAPSE/PASP is a useful marker for identifying ischemia in this population.
- These novel scores aid in cardiovascular risk assessment for SCTD patients.
Background:
Cardiovascular diseases are common cause of morbidity and mortality in patients with systemic connective tissue diseases (SCTD) due to accelerated atherosclerosis which couldn't be explained by traditional risk factors (CVDRF).
Hypothesis:
We hypothesized that recently developed score predicting probability of heart failure with preserved ejection fraction (H2 FPEF), as well as a measure of right ventricular-pulmonary vasculature coupling [tricuspid annular plane systolic excursion (TAPSE)/pulmonary artery systolic pressure (PASP) ratio], are predictive of atherosclerosis in SCTD.
Methods:
203 patients (178 females) diagnosed with SCTD underwent standard and stress-echocardiography (SE) with TAPSE/PASP and left ventricular (LV) diastolic filling pressure (E/e') measurements, carotid ultrasound and computed tomographic coronary angiography. Patients who were SE positive for ischemia underwent coronary angiography (34/203). The H2 FPEF score was calculated according to age, body mass index, presence of atrial fibrillation, ≥2 antihypertensives, E/e' and PASP.
Results:
Mean LV ejection fraction was 66.3 ± 7.1%. Atherosclerosis was present in 150/203 patients according to: 1) intima-media thickness>0.9 mm; and 2) Agatstone score > 300 or Syntax score ≥ 1. On binary logistic regression analysis, including CVDRF prevalence, echocardiographic parameters and H2 FPEF score, only H2 FPEF score remained significant for the prediction of atherosclerosis presence (χ2 = 19.3, HR 2.6, CI 1.5-4.3, p < 0.001), and resting TAPSE/PASP for the prediction of a SE positive for ischemia (χ2 = 10.4, HR 0.01, CI = 0.01-0.22, p = 0.004). On ROC analysis, the optimal threshold value for identifying patients with atherosclerosis was a H2 FPEF score ≥2 (Sn 60.4%, Sp 69.4%, area 0.67, SE = 0.05, p < 0.001).
Conclusions:
H2 FPEF score and resting TAPSE/PASP demonstrated clinical value for an atherosclerosis diagnosis in patients diagnosed with SCTD.
Related Concept Videos
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Atherosclerosis III: Management
Atherosclerosis I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Acute Coronary Syndrome III: Diagnostic Studies

